Login to Your Account



Regeneron, Bayer testing AMD Ang2 breakthrough in $130M combo eye deal

By Randy Osborne
Staff Writer

Thursday, March 24, 2016

With sales of VEGF trap Eylea as a monotherapy possibly slowing down, Regeneron Pharmaceuticals Inc. and Bayer AG have broadened their work in eye disease with a new $130 million agreement to test the treatment in combination with the Ang2 antibody nesvacumab.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription